LDL-C降低75%!齐鲁制药/瑞博生物降脂siRNA疗法启动III期临床

医药魔方Info
Feb 28

2月27日,美国临床试验收录网站显示,齐鲁制药引进的小核酸新药QLC7401(RBD7022)启动了首个III期临床试验,旨在评估该药物(100mg,皮下注射)联合降脂药物治疗伴低密度脂蛋白胆固醇(LDL-C)升高的原发性高胆固醇血症或混合性高脂血症的有效性和安全性。RBD7022是瑞博生物基于其自主创新的RIBO-GalSTAR®肝靶向递送技术开发的GalNAc缀合siRNA药物,旨在通过靶向...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10